000516IMICSZSE

Xi'an International Medical Investment Company Limited

国际医学

000516

Shenzhen Stock Exchange

BoardMain Board of Shenzhen Stock Exchange
IndustryHealth
ISINCNE000000016
ListedAugust 9, 1993
Websitewww.000516.cn
IR EmailIMIC@000516.cn
Phone029-88330516
Sourcecninfo.com.cn
AddressSecurity Building, Xi'an International Medical Center Hospital, No. 777, Xitai Road, High-tech Zone, Xi'an, Shaanxi

Company Overview

Xi'an International Medical Investment Company Limited, listed on the Shenzhen Stock Exchange since 1993, is a prominent player in the health and social works sector. The company focuses on providing comprehensive medical services and the application of modern medical technologies. It operates two major hospitals, Xi’an International Medical Gaoxin Hospital and Xi’an International Medical Center Hospital, and actively implements the "Internet + Medicine" model to enhance its service offerings. The company aims to integrate various aspects of healthcare, including treatment, research, teaching, and rehabilitation, to address the growing demand for medical services. The company's main business lines include the development of a cross-regional medical consortium, investment in advanced medical technologies such as stem cells, and the establishment of a life cycle grand health service platform. Xi'an International Medical has formed strategic partnerships with renowned medical institutions and enterprises globally, enhancing its market position. The company is committed to expanding its medical service network throughout Western China and aims to build a large health industry chain through synergetic development, positioning itself as a leading health management group in the region.

AI-generated from company disclosures and CNInfo data.

Company Profile

As the first listed company in Shaanxi Province and northwestern china, in recent years, the company has focused its development strategy on the medical service and modern medical technology, constantly improving its corporate governance, and formed development strategy with scientific and technological innovation and steady operation, at the same time, the capital strength is keep growing, and the company now become one of the largest listed medical industry groups. The Company uses superior resources to accelerate development of its main business and its medical service business is growing rapidly. Two comprehensive hospital campuses of the Company, Xi’an International Medical Center Hospital (JCI accredited hospital) , Gaoxin Hospital (the first private Grade-3 Class-A hospital in China) are fully utilized to effectively expand the operation of the Company and improve its medical business strength. The industrial impact and market competitiveness of the Company have been significantly improved, which marks the formation of its cross-regional medical service network around Xi’an proper. This is a milestone of the Company in setting up a life cycle grand health service platform with medical services at the core. In the future, the company will be devoted to the construction of medical service network covering Western China with capital as the link; By tracking advanced medical science and technologies, the Company will continue to invest more in the fields of medical services and high-tech life science, build a large health industry chain with synergetic development, and develop into a health management group with great influence in China. The Company focuses the grand health industry and cooperates with domestic and overseas strategic partners deeply to promote development of the health industry of China. Its partners include famous medical service institutions, medical instrument enterprises in the United States, Britain, Japan, Germany, South Korea. In 2021, Xi’an International Medical Center Hospital, and Xi'an Gaoxin Hospital officially join Mayo Clinic Care Network. Through this network Mayo Clinic will share knowledge, expertise and resources with International Medical, and work together to advance medical science and enhance the delivery of care. The assisted reproductive medical project of the Company was approved by the health administration at the beginning of 2019. Now the Company has officially started the intrauterine insemination (IUI) service. The Company will carry out in vitro fertilization (IVF) business after obtaining approval from the health administration. In addition, the Company maintains in-depth exchanges and cooperation with famous domestic and international medical institutions, to introduce excellent talents, advanced technologies and service ideas, as well as builds leading disciplines. The Company aims to establish multinational and cross-regional medical cooperative mechanisms with high-quality medical institutions, so as to provide satisfactory medical services for patients and meet their differential medical demands.

55 announcements tracked· Last: July 31, 2026

Key Financials

As of 2026-07-25T00:00:00.000+00:00
Revenue¥969.4M
Net Profit-¥48.3M
ROE-1.48%
Debt Ratio69.11%
Monetary Funds¥375.2M
Receivables¥455.5M
Total Shares2.24bn

Announcements

55 totalCSV

Notes & Comments

Sign in to leave a comment or private note.

No notes or comments yet.